Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | INMT | O95050 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21584067 | 0.86 | INMT (0.39) | INMT | |
| SCHEMBL13684184 | 0.76 | INMT (0.52) | INMT | |
| SCHEMBL11175294 | 0.71 | MAPT (0.33) | INMT | |
| SCHEMBL19449153 | 0.68 | POLB (0.32) | INMTPOLB | |
| SCHEMBL611663 | 0.66 | POLB (0.35) | POLB | |
| SCHEMBL13698409 | 0.66 | POLB (0.35) | POLB | |
| SCHEMBL13199319 | 0.64 | — | — | |
| SCHEMBL13684180 | 0.64 | INMT (0.54) | INMT | |
| SCHEMBL1698643 | 0.63 | — | — | |
| SCHEMBL12570386 | 0.63 | NOTUM (0.51) | POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240024318-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-11723980-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-08-15 | — | — | US | disclosed |
| US-11679109-B2 | SMARCA degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-20210221822-A1 | TRICYCLIC DERIVATIVES INHIBITOR, PREPARATION METHOD, AND APPLICATIONS THEREOF | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2021-07-22 | — | — | US | disclosed |
| US-20210145824-A1 | MODULATORS OF CELLULAR ADHESION | NOVARTIS PHARMACEUTICALS CORPORATION (US) | 2021-05-20 | — | — | US | disclosed |
| US-20200281202-A1 | NOVEL FUNGICIDAL HETEROCYCLIC COMPOUNDS | PI INDUSTRIES LTD. (IN) | 2020-09-10 | — | — | US | disclosed |
| WO-2020020385-A1 | TRICYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION | 上海翰森生物医药科技有限公司 | 2020-01-30 | — | — | WO | disclosed |
| US-9504728-B2 | Dosage form | NEUROVIVE PHARMACEUTICAL AB (SE) | 2016-11-29 | — | — | US | disclosed |
| US-20160074381-A1 | MODULATORS OF CELLULAR ADHESION | SARCODE BIOSCIENCE INC. (US) | 2016-03-17 | — | — | US | disclosed |
| US-9248126-B2 | Modulators of cellular adhesion | SARCODE BIOSCIENCE INC. (US) | 2016-02-02 | — | — | US | disclosed |
| US-20120035154-A1 | Modulators of Cellular Adhesion | SARcode Bioscience, Inc. (US) | 2012-02-09 | — | — | US | disclosed |
| US-8071617-B2 | Modulators of cellular adhesion | SARCODE BIOSCIENCE INC. (US) | 2011-12-06 | — | — | US | disclosed |
| US-7989626-B2 | Modulators of cellular adhesion | SAR code Corporation (US) | 2011-08-02 | — | — | US | disclosed |
| US-20110124625-A1 | Modulators of Cellular Adhesion | SARCODE CORPORATION (US) | 2011-05-26 | — | — | US | disclosed |
| US-20110124669-A1 | Modulators of Cellular Adhesion | SARCODE CORPORATION (US) | 2011-05-26 | — | — | US | disclosed |
| US-7790743-B2 | Modulators of cellular adhesion | SARCODE CORPORATION (US) | 2010-09-07 | — | — | US | disclosed |
| US-7745460-B2 | Modulators of cellular adhesion | SARCODE CORPORATION (US) | 2010-06-29 | — | — | US | disclosed |
| US-20080182839-A1 | MODULATORS OF CELLULAR ADHESION | SUNESIS PHARMACEUTICALS, INC. (US) | 2008-07-31 | — | — | US | disclosed |
| US-20080176896-A1 | Modulators of cellular adhesion | BAUSCH + LOMB IRELAND LIMITED (IE) | 2008-07-24 | — | — | US | disclosed |
| US-7314938-B2 | Immune and/or inflammatory disorders; autoimmune disorders; disorders mediated by the CD11/CD18 family of cellular adhesion molecules (e.g., LFA-1); antagonize CD11/CD18 receptors associated with leukocytes. | SUNESIS PHARMACEUTICALS, INC. (US) | 2008-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210145824-A1 | MODULATORS OF CELLULAR ADHESION | ITGB1, VCAM1, ITGB8 | INMT 4348/4885POLB 4427/4885 |
| US-20080176896-A1 | Modulators of cellular adhesion | ITGB1, VCAM1, ITGB8 | INMT 4348/4885POLB 4427/4885 |
| US-20210221822-A1 | TRICYCLIC DERIVATIVES INHIBITOR, PREPARATION METHOD, AND APPLICATIONS THEREOF | PIK3CA, PIK3CD, PIK3CB | INMT 1978/4885POLB 765/4885 |
| US-20240024318-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCA2, SMARCC2 | INMT 903/4885POLB 22/4885 |
| US-11723980-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | INMT 1213/4885POLB 2088/4885 |
| US-20110124625-A1 | Modulators of Cellular Adhesion | ITGB1, VCAM1, ITGB8 | INMT 4348/4885POLB 4427/4885 |
| US-20200281202-A1 | NOVEL FUNGICIDAL HETEROCYCLIC COMPOUNDS | CYP1B1, CYP1A1, CYP51A1 | INMT 928/4885POLB 4347/4885 |
| US-20160074381-A1 | MODULATORS OF CELLULAR ADHESION | ITGB1, VCAM1, ITGB8 | INMT 4348/4885POLB 4427/4885 |
| US-11679109-B2 | SMARCA degraders and uses thereof | SMARCA1, SMARCA2, SMARCC2 | INMT 903/4885POLB 22/4885 |
| US-20110124669-A1 | Modulators of Cellular Adhesion | ITGB1, VCAM1, ITGB8 | INMT 4348/4885POLB 4427/4885 |
| US-20120035154-A1 | Modulators of Cellular Adhesion | ITGB1, VCAM1, ITGB8 | INMT 4348/4885POLB 4427/4885 |
| US-20080182839-A1 | MODULATORS OF CELLULAR ADHESION | ITGB1, VCAM1, ITGB8 | INMT 4369/4885POLB 4445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.